Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 Recruiting
46 enrolled
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Phase 3 Recruiting
158 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
LITESPARK-033
Phase 3 Recruiting
904 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
REZILIENT2
Phase 2 Recruiting
220 enrolled
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Phase NA Recruiting
410 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 Recruiting
140 enrolled
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
Phase 2 Recruiting
90 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Phase 2 Recruiting
189 enrolled
TROPION-Lung15
Phase 3 Recruiting
744 enrolled
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
ARTACUS
Phase 1/2 Recruiting
90 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
50 enrolled
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Phase 1/2 Recruiting
430 enrolled
INDIGO
Phase NA Recruiting
51 enrolled
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Phase 2 Recruiting
43 enrolled
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Phase 1/2 Recruiting
27 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Recruiting
2,000 enrolled
A Study of PHN-012 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
165 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Phase 1/2 Recruiting
110 enrolled
SMARAGD
Recruiting
1,975 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer
Recruiting
346 enrolled
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Phase 2 Recruiting
21 enrolled
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
1,410 enrolled
OCAPI
Recruiting
20 enrolled
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Recruiting
450 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Recruiting
39 enrolled
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 Recruiting
27 enrolled
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Phase 1/2 Recruiting
38 enrolled
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2 Recruiting
20 enrolled
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
Phase NA Recruiting
48 enrolled
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase 2 Recruiting
52 enrolled
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 Recruiting
170 enrolled
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 Recruiting
455 enrolled
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Phase 2 Recruiting
50 enrolled
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Recruiting
471 enrolled
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 Recruiting
32 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
TARE
Phase 2 Recruiting
30 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled
TraveraRTGx
Recruiting
200 enrolled